PHILADELPHIA, PA — Latus Bio said it will present new preclinical and computational data related to experimental gene therapies for Huntington’s disease and CLN2 disease at the ASGCT 2026 Annual Meeting taking place May 11-15.
The company said the data support plans to advance its LTS-201 and LTS-101 programs into clinical development later this year.
Latus Bio said one oral presentation and two poster sessions will focus on Huntington’s disease modeling, biodistribution studies, toxicology findings, and gene therapy delivery data.
According to the company, LTS-201 is designed to reduce somatic instability in Huntington’s disease by lowering MSH3 expression through an adeno-associated virus gene therapy approach.
The company said computational simulations suggest therapies targeting somatic instability could delay motor symptom onset and disease progression by more than a decade when administered early.
Preclinical studies involving nonhuman primates and Huntington’s disease mouse models showed reductions in MSH3 expression and targeted biodistribution in disease-relevant brain regions, according to Latus Bio.
“These data are highly supportive of the applications of our gene therapy platform to larger disease populations, beginning with Huntington’s disease,” said Jang-Ho Cha, chief scientific and medical officer at Latus Bio.
Cha said the company expects to submit an investigational new drug application for LTS-201 during the third quarter of 2026.
Latus Bio also reported new toxicology and biodistribution data for LTS-101, an investigational therapy for CLN2 disease, also known as Batten disease.
The company said studies in nonhuman primates showed the therapy was well tolerated through six months following administration and produced sustained levels of TPP1 protein in cerebrospinal fluid.
According to Latus Bio, first-in-human studies for LTS-101 are planned for the third quarter of 2026 following investigational new drug clearance received in December 2025.
Separately, Beverly Davidson, founder of Latus Bio, received the Outstanding Achievement Award from the American Society of Gene and Cell Therapy.
The award is the organization’s highest honor and recognizes contributions to gene therapy research and inherited neurological disease treatment development.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.